期刊文献+

ω-3脂肪酸抑制SW480结肠癌干细胞生长的研究 被引量:2

Inhibitory effect of ω-3 fatty acids on growth of SW480 colon cancer stem cells
原文传递
导出
摘要 目的:探讨ω-3脂肪酸对SW480结肠癌干细胞增殖及血管内皮生长因子(VEGF),syndecan-1,Ki-67基因表达的影响。方法:用流式细胞仪分选出SW480细胞中的CD133+/CD44+/ESA+细胞亚群(SW480结肠癌干细胞),将结肠癌干细胞分用系列浓度(15,30,60μg/μL)的EPA(二十碳五烯酸),系列浓度(15,30,60μg/μL)的DHA(二十二碳六烯酸)及溶剂处理(对照组),用MTT法检测各组细胞的增殖情况;并用RT-PCR检测DHA(60μg/μL)或EPA(60μg/μL)处理后结肠癌干细胞VEGF,syndecan-1和Ki-67表达的变化。结果:低浓度(15μg/μL)的DHA和EPA对结肠癌干细胞的生长无明显影响(均P>0.05),中、高(30,60μg/μL)浓度的EPA和DHA能明显抑制结肠癌干细胞的生长,与对照组比较差异均有统计学意义(均P<0.05)。60μg/μL的EPA及DHA能明显抑制syndecan-1和Ki-67基因的表达,与对照组比较差异均有统计学意义(均P<0.05),但两者对VEGF基因的表达无明显影响(均P>0.05)。结论:ω-3脂肪酸可抑制SW480结肠癌干细胞的增殖,其机制可能与抑制syndecan-1和Ki-67的表达有关。 Objective: To investigate the effect of ω-3 fatty acids on the proliferation and gene expressions of vascular endothelial growth factor (VEGF), syndecan-1 and Ki-67 of SW480 colon cancer stem cells. Methods: The CD133+/CD44+/ESA+ cell subgroups (SW480 colon cancer stem cells) in the SW480 colon cancer cells were sorted by flow cytometr)n Then, the colon cancer cells were treated with serial concentrations (15, 30, 60 μg/gL) ofEPA (eicosapentaenoic acid) or serial concentrations (15, 30, 60 μg/μL) ofDHA (docose hexaenoie acid), or vehicle (control), and the cell proliferations of each cell group were determined by MTT assa)n Furthermore, the gene expressions ofVEGF, syndecan-1 and Ki-67 in colon cancer cells after treatment of EPA (60 μg/μL) or DHA (60 μg/μL) were analyzed by RT-PCR method. Results: Both low concentrations of EPA and DHA had no noticeable effect on the growth of colon cancer cells (both P〈0.05), while either medium or high concentration (30 and 60 μg/μL) of EPA and DHA significantly inhibited the growth of colon cancer cells, which had statistical differences compared with control group (all P〈0.05). Both EPA and DHA at a concentration of 60μg/μL)could significantly suppress the gene expression of syndecan-1 and Ki-67 (both P〈0.05), but showed no evident effect on VEGF gene expression (both P〉0.05). Condusion:ω-3 fatty acids can inhibit the proliferation of SW480 colon cancer stem cells, and the mechanism is probably associated with its suppression ofsyndecan-1 and Ki-67 expression.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2012年第10期1227-1230,共4页 China Journal of General Surgery
关键词 结肠肿瘤 肿瘤干细胞 结肠癌 脂肪酸类ω-3 Colonic Neoplasms Neoplastic Stem Cells FattyAcids,ω-3
  • 相关文献

参考文献14

二级参考文献88

共引文献43

同被引文献21

  • 1Vincenzi B,Frezza AM,Schiavon G. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox Ⅳ[J].{H}SUPPORTIVE CARE IN CANCER,2013,(05):1313-1319. 被引量:1
  • 2Georgiou PA,Tekkis PP,Constantinides VA. Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer[J].{H}EUROPEAN JOURNAL OF CANCER,2013,(01):72-81. 被引量:1
  • 3Mirakhorli M,Rahman SA,Abdullah S. Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy[J].Mol Med Rep,2013,(02):613-617. 被引量:1
  • 4Ng SC,Lau JY,Chan FK. Increased risk of advanced neoplasms among asymptomatic siblings of patients with colorectal cancer[J].{H}GASTROENTEROLOGY,2013,(03):544-550. 被引量:1
  • 5Landry JC,Feng Y,Cohen SJ. Phase 2 study of preoperative radiation with concurrent capecitabine,oxaliplatin,and bevacizumab followed by surgery and postoperative 5-fluorouracil,leucovorin,oxaliplatin (FOLFOX),and bevacizumab in patients with locally advanced rectal cancer:ECOG 3204[J].{H}CANCER,2013,(08):1521-1527. 被引量:1
  • 6Vincenzi B,Zoccoli A,Schiavon G. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients[J].{H}EUROPEAN JOURNAL OF CANCER,2013,(06):1501-1508. 被引量:1
  • 7Infante JR,Bendell JC,Goff LW. Safety,pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody,KRN330,in patients with advanced colorectal cancer[J].{H}EUROPEAN JOURNAL OF CANCER,2013,(06):1169-1175. 被引量:1
  • 8Yeh YS,Tsai HL,Ma CJ. A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients[J].{H}CHEMOTHERAPY,2012,(05):411-418. 被引量:1
  • 9Printz C. Patients with advanced lung,colorectal cancer overly optimistic about chemotherapy[J].{H}CANCER,2013,(04):703. 被引量:1
  • 10Lee KH,Chang HJ,Han SW. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer[J].{H}Cancer Chemotherapy and Pharmacology,2013,(04):843-851. 被引量:1

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部